CurrentUnitedHealthcarePolicy N/A

Sapropterin (Javygtor, Kuvan, Zelvysia) prior authorization

Defines prior authorization and reauthorization requirements for sapropterin products (Javygtor, Kuvan, Zelvysia, generic sapropterin) for treatment of BH4-responsive PKU; applies to UnitedHealthcare pharmacy benefit plans.

Policy Summary

PayerUnitedHealthcare

PolicySapropterin (Javygtor, Kuvan, Zelvysia) prior authorization

Policy CodePolicy N/A

Change TypeMaterial updates — product addition and clinical/review revisions

Effective DateFeb 1, 2026

Next Review DateNov 1, 2025

Key ActionObtain prior authorization and document that the patient is on a Phe-restricted diet and not using Palynziq or Sephience.

SourceLink

POLICY UPDATE CHANGES

Zelvysia was added to the program.

Sephience (sepiapterin) was added to the list of medications that must not be used in combination with sapropterin products.

Authorization period was updated to 12 months for initial and reauthorization approvals.

Brand Kuvan and Javygtor are typically excluded from coverage; plan specifics should be checked for exclusion or tried/failed criteria.

12 monthsAuthorization duration (initial & reauthorization)

≥1 monthMinimum labeled age for indication

3 namesNamed products covered

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

No Palynziq/Sephience

Combination restriction

Coverage Criteria for Sapropterin Products

Initial Authorization

Covered when ALL of the following are met:

Initial Authorization: a. Diagnosis of phenylketonuria (PKU)

Authorization issued for 12 months

Initial Authorization - Diet: b. Patient is actively on a Phe-restricted diet

Initial Authorization - Combination use: c. Patient is not receiving the requested medication in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin)

Reauthorization

Covered when ALL of the following are met:

Reauthorization - Diet: a. Patient is actively on a Phe-restricted diet

12-month authorization

Reauthorization - Response: b. Blood Phe levels continue to remain lower than baseline level

Reauthorization - Combination use: c. Patient is not receiving the requested medication in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin)

Brand formulations Kuvan and Javygtor are typically excluded from coverage for the majority of UnitedHealthcare pharmacy benefits; some plans may require a tried/failed step before coverage of these brands or may not cover them at all. Always perform a member-specific benefit check to confirm whether the brand is excluded or subject to step edits for the member’s plan, and follow any plan-level tried/failed requirements when they are present.

Initial Therapy

Covered when ALL of the following are met:

Initial Therapy: a. Diagnosis of phenylketonuria (PKU)

Authorization issued for 12 months

Initial Therapy - Diet: b. Patient is actively on a Phe-restricted diet

Initial Therapy - Combination use: c. Patient is not receiving the requested medication in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin)

Reauthorization / Continuation Criteria

Reauthorization

Covered when ALL of the following are met:

Reauthorization - Diet: a. Patient is actively on a Phe-restricted diet

12-month authorization

Reauthorization - Response: b. Blood Phe levels continue to remain lower than baseline level

Reauthorization - Combination use: c. Patient is not receiving the requested medication in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin)

Provider Actions and Operational Notes

Prior Authorization

Prior Authorization Required

Prior authorization is required. UnitedHealthcare will approve initial authorization or reauthorization when the policy's clinical criteria are met. Expect approvals to be issued for 12 months when criteria are satisfied. Claim- or diagnosis-level evidence (including ICD-10 codes), prior medication or claim history, and documentation demonstrating a Phe-restricted diet and clinical response (for reauthorization: blood Phe lower than baseline) should be available with the request.

Prior authorization required for Javygtor, Kuvan, sapropterin dihydrochloride, and Zelvysia — approvals issued for 12 months when criteria met
Documentation expectations: diagnosis of phenylketonuria (PKU), evidence patient is actively on a Phe-restricted diet, baseline and follow-up blood Phe levels (for reauthorization), and medication history
Claims/diagnosis evidence: ICD-10 code(s) and prior claim or pharmacy history may be used to support automated approvals

Documentation Required

Automated Approval and Documentation

Step Therapy and Benefit Exclusions

Guidance	Where to check / next steps
Plan-specific exclusions may apply (Javygtor and brand Kuvan are typically excluded); tried/failed criteria may be required.	Verify member-specific benefit plan documents or the payer's benefit portal to confirm exclusion status and any tried/failed step requirements.
Step edits (prior authorization, step therapy, or other utilization controls) can vary by benefit; coverage may be further restricted by state mandates or federal requirements.	Check the member’s plan-specific utilization management rules, prior authorization criteria, and state-specific mandates via the benefits portal or plan policy documents before submitting a request.
Authorization durations are typically issued for 12 months when criteria are met.	Confirm prior authorization duration and any supply limits in the member’s benefit details or prior authorization response portal.

Definitions

BH4-responsive PKU — definition

DefinitionHyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU)

Clinical descriptionA form of PKU in which elevated blood phenylalanine (Phe) levels are responsive to BH4 (tetrahydrobiopterin) therapy

Age indicationApplies to adult and pediatric patients one month of age and older

Treatment contextManaged with a Phe‑restricted diet in conjunction with BH4-responsive therapies (e.g., sapropterin products: Javygtor, Kuvan, Zelvysia)

Therapeutic goalReduction of blood phenylalanine (Phe) levels

Background

Sapropterin products — marketed as Javygtor, Kuvan, generic sapropterin dihydrochloride, and Zelvysia — are phenylalanine hydroxylase activators indicated to reduce blood phenylalanine (Phe) levels in adults and pediatric patients one month of age and older with hyperphenylalaninemia due to BH4‑responsive phenylketonuria (PKU). These agents are used in conjunction with a Phe‑restricted diet to lower blood Phe. Authorization for these products under this policy is issued for 12 months; plan-specific coverage rules and member benefits may further affect coverage.

Revision History

2025-11-01additionLatest

Zelvysia (sapropterin dihydrochloride) was added to the program.

2025-11-01restriction_update

Sephience (sepiapterin) was added to the list of medications that must not be used in combination with sapropterin products.

2024-03-01authorization_duration_change

Authorization approval duration updated to 12 months.

Policy Summary

PayerUnitedHealthcare

PolicySapropterin (Javygtor, Kuvan, Zelvysia) prior authorization

Policy CodePolicy N/A

Change TypeMaterial updates — product addition and clinical/review revisions

Effective DateFeb 1, 2026

Next Review DateNov 1, 2025

Key ActionObtain prior authorization and document that the patient is on a Phe-restricted diet and not using Palynziq or Sephience.

SourceLink

On This Page

UnitedHealthcare may use automated approval and reauthorization processes. Approvals can be granted based solely on prior claims, medication history, ICD-10 diagnosis codes, or claim-logic without additional documentation. Supply limits or quantity restrictions may apply; include expected supply request (days or units) in the prior authorization submission when applicable.

Automated approval possible using prior claims/pharmacy history and ICD-10 diagnosis
Include requested supply (quantity/days) to ensure limits are applied correctly
Use of automation varies by program/therapeutic class

Step Therapy

Exclusions and Step Requirements

Plan-specific exclusions and step-therapy may apply. Brand Kuvan and Javygtor are typically excluded from coverage; tried-and-failed criteria or step requirements may be required before a non-excluded formulation will be approved. Always verify the member's benefit plan and any state or federal mandates that may affect coverage.

Javygtor and Brand Kuvan are typically excluded — check member-specific plan for exclusion/step-therapy status
Tried/failed requirements may be required for coverage of certain formulations
State mandates and federal regulatory requirements may affect coverage

Denial Risk

Denial Triggers

Denial triggers include missing or insufficient documentation of a Phe-restricted diet, combination use with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin), absence of a PKU diagnosis, or failure to show clinical response where required for reauthorization. Requests that conflict with the policy's exclusions or that exceed supply limits may also be denied.

Denial triggers: no evidence patient is on a Phe-restricted diet
Denial triggers: requested medication used in combination with Palynziq or Sephience
Denial triggers: missing PKU diagnosis or required blood Phe data for reauthorization
Denial triggers: requests for typically excluded products (e.g., Brand Kuvan, Javygtor) without plan-specific exception or step-therapy completion
Denial triggers: exceeding any plan supply limits

2021-07-01authorization_duration_change

Re-authorization approval duration updated to 12 months (noted in document history).